ECSP12012056A - Derivados de 3-hidroxi-5-arilisotiazol novedosos - Google Patents
Derivados de 3-hidroxi-5-arilisotiazol novedososInfo
- Publication number
- ECSP12012056A ECSP12012056A ECSP12012056A ECSP12012056A EC SP12012056 A ECSP12012056 A EC SP12012056A EC SP12012056 A ECSP12012056 A EC SP12012056A EC SP12012056 A ECSP12012056 A EC SP12012056A
- Authority
- EC
- Ecuador
- Prior art keywords
- compound
- ring
- salt
- novedosos
- arilisotiazol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 abstract 1
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 abstract 1
- 229940125827 GPR40 agonist Drugs 0.000 abstract 1
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 abstract 1
- 229940122199 Insulin secretagogue Drugs 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Proporcionar un agente que activa GPR40 que tiene, como un ingrediente activo, un compuesto novedoso que tiene una acción agonista GPR40, una sal del compuesto, un solvato de la sal o el compuesto, o similares, particularmente, un secretagogo de insulina y y un agente terapéutico y/o profiláctico contra diabetes, obesidad, u otras enfermedades.Medios para solucionar el problemaUn compuesto de la Fórmula (I): donde n es 0 hasta 2; p es 0 hasta 4; j es 0 hasta 3; k es 0 hasta 2; un anillo A es un grupo arilo que está opcionalmente sustituido con L o un grupo heterocíclico que está opcionalmente sustituido con L; un anillo B es un anillo de benceno, un anillo de piridina, o un anillo de pirimidina;X es O, S, -NR7-; y R1 hasta R7 son grupos específicos,una sal del compuesto, o un solvato de la sal o el compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009295855 | 2009-12-25 | ||
| JP2010043420 | 2010-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12012056A true ECSP12012056A (es) | 2012-10-30 |
Family
ID=44195895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12012056 ECSP12012056A (es) | 2009-12-25 | 2012-07-23 | Derivados de 3-hidroxi-5-arilisotiazol novedosos |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8476287B2 (es) |
| EP (1) | EP2518060A4 (es) |
| JP (2) | JP5002077B2 (es) |
| KR (1) | KR20130004262A (es) |
| CN (2) | CN102712610B (es) |
| AU (1) | AU2010336225A1 (es) |
| BR (1) | BR112012015612A2 (es) |
| CA (1) | CA2785674A1 (es) |
| CL (1) | CL2012001722A1 (es) |
| CO (1) | CO6650337A2 (es) |
| CR (1) | CR20120345A (es) |
| EA (1) | EA201290574A1 (es) |
| EC (1) | ECSP12012056A (es) |
| GT (1) | GT201200217A (es) |
| HN (1) | HN2012001351A (es) |
| IL (1) | IL220616A0 (es) |
| MA (1) | MA33952B1 (es) |
| MX (1) | MX2012007474A (es) |
| NI (1) | NI201200113A (es) |
| NZ (1) | NZ601408A (es) |
| PE (1) | PE20121639A1 (es) |
| PH (1) | PH12012501456A1 (es) |
| RU (1) | RU2567755C2 (es) |
| SG (1) | SG181961A1 (es) |
| WO (1) | WO2011078371A1 (es) |
| ZA (1) | ZA201203416B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2779398A1 (en) | 2009-10-30 | 2011-05-05 | Mochida Phamaceutical Co., Ltd. | Novel 3-hydroxy-5-arylisoxazole derivative |
| AU2010336225A1 (en) | 2009-12-25 | 2012-08-16 | Mochida Pharmaceutical Co.,Ltd. | Novel 3-hydroxy-5-arylisothiazole derivative |
| US8581584B2 (en) * | 2010-05-26 | 2013-11-12 | Florida State University Research Foundation | Membrane proteins, mechanisms of action and uses thereof |
| JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
| EP2677869B1 (en) | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| AU2012248629A1 (en) * | 2011-04-27 | 2013-11-28 | Mochida Pharmaceutical Co., Ltd. | Novel 3-hydroxyisothiazole 1-oxide derivative |
| AU2012248627A1 (en) | 2011-04-28 | 2013-11-14 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
| WO2013154163A1 (ja) * | 2012-04-11 | 2013-10-17 | 持田製薬株式会社 | 新規５－アリール－１，２－チアジナン誘導体 |
| CN106977495B (zh) | 2012-04-24 | 2020-08-04 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
| AU2013290100A1 (en) | 2012-07-11 | 2015-01-29 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| CA2880901A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
| HRP20211855T1 (hr) | 2013-03-12 | 2022-03-04 | Vertex Pharmaceuticals Incorporated | Inhibitori dnk-pk |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| PE20161022A1 (es) | 2013-10-17 | 2016-11-12 | Vertex Pharma | Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5´-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteinas quinasa dependientes de adn |
| HK1221465A1 (zh) | 2013-11-14 | 2017-06-02 | Cadila Healthcare Limited | 新型杂环化合物 |
| KR20170122782A (ko) * | 2015-02-27 | 2017-11-06 | 난트바이오사이언스 인코포레이티드 | 키나아제 억제제로서의 피리미딘 유도체 및 그 치료적 용도 |
| JP6616244B2 (ja) * | 2015-05-29 | 2019-12-04 | 北興化学工業株式会社 | 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法 |
| KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| AU2019222644B2 (en) | 2018-02-13 | 2021-04-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| SI3820572T1 (sl) | 2018-07-13 | 2023-12-29 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN110066254B (zh) * | 2018-11-16 | 2021-03-19 | 温州大学 | 一种异噻唑-3-酮化合物的制备方法 |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| EP4153589A4 (en) | 2020-05-19 | 2024-06-12 | Kallyope, Inc. | AMPK ACTIVATORS |
| EP4172162A4 (en) | 2020-06-26 | 2024-08-07 | Kallyope, Inc. | AMPK ACTIVATORS |
| CN115433143B (zh) * | 2021-06-03 | 2023-10-13 | 中国科学院大连化学物理研究所 | 一种异噻唑啉酮类化合物的合成方法 |
| CN115386028B (zh) * | 2022-08-26 | 2023-06-23 | 长春理工大学 | 一种聚合度可控的聚山梨酸-d-薄荷醇酯及合成方法与应用 |
| CN117510431A (zh) * | 2023-11-08 | 2024-02-06 | 浙江雅辰药物科技股份有限公司 | 一种异噻唑-3-酮及其衍生物、合成方法 |
| WO2025140655A1 (en) * | 2023-12-30 | 2025-07-03 | Fujian Haixi Pharmaceuticals Co., Ltd. | Heteroaryl compounds as multi-target protein kinase inhibitors |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3562283A (en) | 1968-07-01 | 1971-02-09 | Rohm & Haas | 1-oxo and 1,1-dioxo-3-isothiazolones |
| US3801575A (en) * | 1972-01-24 | 1974-04-02 | Rohm & Haas | 3-hydroxyisothiazoles |
| WO1997031906A1 (en) | 1996-02-27 | 1997-09-04 | Sankyo Company, Limited | Isoxazole derivatives |
| CN1149204C (zh) | 1999-01-13 | 2004-05-12 | 沃尼尔·朗伯公司 | 1-杂环取代的二芳基胺 |
| JP2000204077A (ja) * | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
| WO2004011446A1 (en) | 2002-07-26 | 2004-02-05 | Bayer Pharmaceuticals Corporation | Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics |
| US7553867B2 (en) | 2002-09-06 | 2009-06-30 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| JP4594611B2 (ja) * | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
| AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| CA2527691C (en) | 2003-05-30 | 2013-01-22 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| US7141596B2 (en) | 2003-10-08 | 2006-11-28 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
| WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
| RU2006126978A (ru) | 2003-12-25 | 2008-01-27 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 3-(4-бензилоксифенил)пропановой кислоты |
| KR20070004769A (ko) | 2004-02-27 | 2007-01-09 | 암젠 인코포레이션 | 대사 장애의 치료에 사용되는 화합물, 약제학적 조성물 및그 사용방법 |
| SE0500055D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| BRPI0615150A2 (pt) | 2005-08-10 | 2017-06-20 | Takeda Pharmaceuticals Co | agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo |
| CA2621949A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| BRPI0713378A8 (pt) | 2006-06-27 | 2018-01-02 | Takeda Pharmaceutical | composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto |
| EP2064193A1 (en) | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterocyclic gpr40 modulators |
| WO2008033931A1 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib |
| JP5405120B2 (ja) | 2006-12-01 | 2014-02-05 | Ｍｓｄ株式会社 | 新規フェニル−イソキサゾール−３−オール誘導体 |
| ES2446419T3 (es) | 2007-04-16 | 2014-03-07 | Amgen, Inc | Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos |
| MY149648A (en) | 2007-09-21 | 2013-09-30 | Sanofi Aventis | Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament |
| US8030354B2 (en) | 2007-10-10 | 2011-10-04 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
| JP2011016722A (ja) | 2007-10-23 | 2011-01-27 | Astellas Pharma Inc | チアゾリジンジオン化合物 |
| TW200932219A (en) | 2007-10-24 | 2009-08-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| MX2010004435A (es) | 2007-10-26 | 2010-05-13 | Japan Tobacco Inc | Compuestos espiro y uso farmaceutico de los mismos. |
| AU2009220163B2 (en) | 2008-03-06 | 2011-10-06 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| EP2298750A4 (en) | 2008-06-02 | 2012-04-25 | Msd Kk | NOVEL ISOXAZOLE DERIVATIVE |
| CN102076650A (zh) | 2008-06-25 | 2011-05-25 | 第一三共株式会社 | 羧酸化合物 |
| WO2010085525A1 (en) | 2009-01-23 | 2010-07-29 | Schering Corporation | Bridged and fused heterocyclic antidiabetic compounds |
| TW201040186A (en) | 2009-02-05 | 2010-11-16 | Schering Corp | Phthalazine-containing antidiabetic compounds |
| EP2440541A1 (en) | 2009-06-09 | 2012-04-18 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| CA2779398A1 (en) | 2009-10-30 | 2011-05-05 | Mochida Phamaceutical Co., Ltd. | Novel 3-hydroxy-5-arylisoxazole derivative |
| AR078948A1 (es) | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
| AU2010336225A1 (en) | 2009-12-25 | 2012-08-16 | Mochida Pharmaceutical Co.,Ltd. | Novel 3-hydroxy-5-arylisothiazole derivative |
| CN101781268B (zh) | 2010-02-25 | 2012-05-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 异噻唑酮取代的苯二羧酸衍生物及其用于制备β-分泌酶抑制剂的用途 |
| JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
-
2010
- 2010-12-24 AU AU2010336225A patent/AU2010336225A1/en not_active Abandoned
- 2010-12-24 WO PCT/JP2010/073464 patent/WO2011078371A1/ja not_active Ceased
- 2010-12-24 KR KR1020127019581A patent/KR20130004262A/ko not_active Withdrawn
- 2010-12-24 JP JP2011547676A patent/JP5002077B2/ja not_active Expired - Fee Related
- 2010-12-24 CA CA2785674A patent/CA2785674A1/en not_active Abandoned
- 2010-12-24 PE PE2012000884A patent/PE20121639A1/es not_active Application Discontinuation
- 2010-12-24 PH PH1/2012/501456A patent/PH12012501456A1/en unknown
- 2010-12-24 EP EP10839599.7A patent/EP2518060A4/en not_active Withdrawn
- 2010-12-24 MX MX2012007474A patent/MX2012007474A/es active IP Right Grant
- 2010-12-24 NZ NZ601408A patent/NZ601408A/en not_active IP Right Cessation
- 2010-12-24 BR BR112012015612A patent/BR112012015612A2/pt not_active IP Right Cessation
- 2010-12-24 MA MA35101A patent/MA33952B1/fr unknown
- 2010-12-24 SG SG2012047601A patent/SG181961A1/en unknown
- 2010-12-24 CN CN201080059173.0A patent/CN102712610B/zh not_active Expired - Fee Related
- 2010-12-24 CN CN201510033003.XA patent/CN104710381A/zh active Pending
- 2010-12-24 US US13/392,350 patent/US8476287B2/en not_active Expired - Fee Related
- 2010-12-24 RU RU2012131840/04A patent/RU2567755C2/ru not_active IP Right Cessation
- 2010-12-24 EA EA201290574A patent/EA201290574A1/ru unknown
-
2012
- 2012-05-10 ZA ZA2012/03416A patent/ZA201203416B/en unknown
- 2012-05-17 JP JP2012113868A patent/JP2012153726A/ja active Pending
- 2012-06-22 CL CL2012001722A patent/CL2012001722A1/es unknown
- 2012-06-24 IL IL220616A patent/IL220616A0/en unknown
- 2012-06-25 CR CR20120345A patent/CR20120345A/es unknown
- 2012-06-25 GT GT201200217A patent/GT201200217A/es unknown
- 2012-06-25 HN HN2012001351A patent/HN2012001351A/es unknown
- 2012-06-25 CO CO12106432A patent/CO6650337A2/es not_active Application Discontinuation
- 2012-06-25 NI NI201200113A patent/NI201200113A/es unknown
- 2012-07-23 EC ECSP12012056 patent/ECSP12012056A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2011078371A1 (ja) | 2013-05-09 |
| GT201200217A (es) | 2014-02-10 |
| ZA201203416B (en) | 2013-08-28 |
| CN104710381A (zh) | 2015-06-17 |
| CR20120345A (es) | 2012-11-01 |
| AU2010336225A1 (en) | 2012-08-16 |
| CO6650337A2 (es) | 2013-04-15 |
| MX2012007474A (es) | 2012-08-01 |
| RU2567755C2 (ru) | 2015-11-10 |
| CL2012001722A1 (es) | 2012-12-14 |
| RU2012131840A (ru) | 2014-01-27 |
| NI201200113A (es) | 2012-08-13 |
| CN102712610A (zh) | 2012-10-03 |
| KR20130004262A (ko) | 2013-01-09 |
| EA201290574A1 (ru) | 2012-12-28 |
| EP2518060A1 (en) | 2012-10-31 |
| MA33952B1 (fr) | 2013-01-02 |
| JP2012153726A (ja) | 2012-08-16 |
| EP2518060A4 (en) | 2014-01-08 |
| PE20121639A1 (es) | 2012-12-02 |
| IL220616A0 (en) | 2012-08-30 |
| BR112012015612A2 (pt) | 2016-03-15 |
| PH12012501456A1 (en) | 2012-10-29 |
| JP5002077B2 (ja) | 2012-08-15 |
| SG181961A1 (en) | 2012-08-30 |
| US20120157459A1 (en) | 2012-06-21 |
| WO2011078371A1 (ja) | 2011-06-30 |
| CN102712610B (zh) | 2015-03-04 |
| HN2012001351A (es) | 2015-03-23 |
| US8476287B2 (en) | 2013-07-02 |
| CA2785674A1 (en) | 2011-06-30 |
| NZ601408A (en) | 2013-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12012056A (es) | Derivados de 3-hidroxi-5-arilisotiazol novedosos | |
| BR112013027883A2 (pt) | novo derivado de 1-óxido de 3-hidroxiisotiazol | |
| UA111579C2 (uk) | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ | |
| CR20120177A (es) | Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes | |
| MX2020002825A (es) | Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia. | |
| CL2011001497A1 (es) | Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico. | |
| CR10748A (es) | Compuesto de indol | |
| CR10564A (es) | Compuestos cíclicos fusionados | |
| CR20140005A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| ECSP13012611A (es) | Derivados de pirazol-aminopirimidina como moduladores de la lrrk2 | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| PE20120648A1 (es) | Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1 | |
| CO2017006308A2 (es) | Derivados de glucagón | |
| DOP2012000139A (es) | Nuevos compuestos de espiropiperidina | |
| EA201391525A1 (ru) | Гликозидные производные и их применение для лечения диабета | |
| MX394818B (es) | Derivados de tetrahidro-benzo[d]azepina como moduladores de gpr120. | |
| PE20130815A1 (es) | Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos | |
| UY32190A (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibdores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales | |
| DOP2012000058A (es) | Agente terapeutico para trastornos del estado de animo | |
| CL2011002650A1 (es) | Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson. | |
| CR11360A (es) | Benzotiazoles como moduladores del receptor de grelina | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
| SG11201811543XA (en) | Rotigotine behenate, and manufacturing method and application thereof | |
| CY1119483T1 (el) | Θεραπευτικος παραγων για τις αγχωδεις διαταραχες | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer |